1.L.A. Doyle, Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone, Cancer 120 (2014) 1763-1774. 10.1002/cncr.28657.
2.A.J. Saraf, J.M. Fenger, R.D. Roberts, Osteosarcoma: Accelerating Progress Makes for a Hopeful Future, Front Oncol 8 (2018) 4. 10.3389/fonc.2018.00004.
3.A. Luetke, P.A. Meyers, I. Lewis, H. Juergens, Osteosarcoma treatment - where do we stand? A state of the art review, Cancer Treat Rev 40 (2014) 523-532. 10.1016/j.ctrv.2013.11.006.
4.G.M. Shankar, M.J. Clarke, T. Ailon, L.D. Rhines, S.R. Patel, A. Sahgal, I. Laufer, D. Chou, M.H. Bilsky, D.M. Sciubba, M.G. Fehlings, C.G. Fisher, Z.L. Gokaslan, J.H. Shin, The role of revision surgery and adjuvant therapy following subtotal resection of osteosarcoma of the spine: a systematic review with meta-analysis, J Neurosurg Spine 27 (2017). 10.3171/2016.12.SPINE16995.
5.M. Zhang, X. Zhang, Association of MMP-2 expression and prognosis in osteosarcoma patients, Int J Clin Exp Pathol 8 (2015) 14965-14970.
6.R.J. Flores, A.J. Kelly, Y. Li, M. Nakka, D.A. Barkauskas, M. Krailo, L.L. Wang, L. Perlaky, C.C. Lau, M.J. Hicks, T.-K. Man, A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG, Cancer 123 (2017) 144-154. 10.1002/cncr.30272.
7.Z.-L. Wu, Y.-J. Deng, G.-Z. Zhang, E.-H. Ren, W.-H. Yuan, Q.-Q. Xie, Development of a novel immune-related genes prognostic signature for osteosarcoma, Sci Rep 10 (2020) 18402. 10.1038/s41598-020-75573-w.
8.Y. Deng, W. Yuan, E. Ren, Z. Wu, G. Zhang, Q. Xie, A four-methylated LncRNA signature predicts survival of osteosarcoma patients based on machine learning, Genomics 113 (2021) 785-794. 10.1016/j.ygeno.2020.10.010.
9.K. Chen, N. Rajewsky, The evolution of gene regulation by transcription factors and microRNAs, Nat Rev Genet 8 (2007).
10.L.N. Heppler, D.A. Frank, Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors, Trends Cancer 3 (2017) 816-827. 10.1016/j.trecan.2017.10.004.
11.A.S. Bhagwat, C.R. Vakoc, Targeting Transcription Factors in Cancer, Trends Cancer 1 (2015) 53-65.
12.C.M.J. Lucero, O.A. Vega, M.M. Osorio, J.C. Tapia, M. Antonelli, G.S. Stein, A.J. van Wijnen, M.A. Galindo, The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines, J Cell Physiol 228 (2013) 714-723. 10.1002/jcp.24218.
13.F. Villanueva, H. Araya, P. Briceño, N. Varela, A. Stevenson, S. Jerez, F. Tempio, J. Chnaiderman, C. Perez, M. Villarroel, E. Concha, F. Khani, R. Thaler, F. Salazar-Onfray, G.S. Stein, A.J. van Wijnen, M. Galindo, The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis, J Cell Physiol 234 (2019) 13659-13679. 10.1002/jcp.28046.
14.G. Maurizi, N. Verma, A. Gadi, A. Mansukhani, C. Basilico, Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma, Oncogene 37 (2018) 4626-4632. 10.1038/s41388-018-0292-2.
15.M. Ruh, M.P. Stemmler, I. Frisch, K. Fuchs, R. van Roey, J. Kleemann, M. Roas, H. Schuhwerk, R.L. Eccles, A. Agaimy, D. Baumhoer, G. Berx, F. Müller, T. Brabletz, S. Brabletz, The EMT transcription factor ZEB1 blocks osteoblastic differentiation in bone development and osteosarcoma, J Pathol 254 (2021) 199-211. 10.1002/path.5659.
16.Y. Liu, S. Liao, S. Bennett, H. Tang, D. Song, D. Wood, X. Zhan, J. Xu, STAT3 and its targeting inhibitors in osteosarcoma, Cell Prolif 54 (2021) e12974. 10.1111/cpr.12974.
17.S.A. Lambert, A. Jolma, L.F. Campitelli, P.K. Das, Y. Yin, M. Albu, X. Chen, J. Taipale, T.R. Hughes, M.T. Weirauch, The Human Transcription Factors, Cell 172 (2018) 650-665. 10.1016/j.cell.2018.01.029.
18.K. Yoshihara, M. Shahmoradgoli, E. Martínez, R. Vegesna, H. Kim, W. Torres-Garcia, V. Treviño, H. Shen, P.W. Laird, D.A. Levine, S.L. Carter, G. Getz, K. Stemke-Hale, G.B. Mills, R.G.W. Verhaak, Inferring tumour purity and stromal and immune cell admixture from expression data, Nat Commun 4 (2013) 2612. 10.1038/ncomms3612.
19.P. Charoentong, F. Finotello, M. Angelova, C. Mayer, M. Efremova, D. Rieder, H. Hackl, Z. Trajanoski, Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade, Cell Rep 18 (2017) 248-262. 10.1016/j.celrep.2016.12.019.
20.J. Ritter, S.S. Bielack, Osteosarcoma, Ann Oncol 21 Suppl 7 (2010) vii320-vii325. 10.1093/annonc/mdq276.
21.J.C. Wittig, J. Bickels, D. Priebat, J. Jelinek, K. Kellar-Graney, B. Shmookler, M.M. Malawer, Osteosarcoma: a multidisciplinary approach to diagnosis and treatment, Am Fam Physician 65 (2002) 1123-1132.
22.Z.B. Abrams, M. Zucker, M. Wang, A. Asiaee Taheri, L.V. Abruzzo, K.R. Coombes, Thirty biologically interpretable clusters of transcription factors distinguish cancer type, BMC Genomics 19 (2018) 738. 10.1186/s12864-018-5093-z.
23.T.-H. Zhou, J.-Z. Su, R. Qin, X. Chen, G.-D. Ju, S. Miao, Prognostic and Predictive Value of a 15 Transcription Factors (TFs) Panel for Hepatocellular Carcinoma, Cancer Manag Res 12 (2020) 12349-12361. 10.2147/CMAR.S279194.
24.B. Zhang, H. Wang, Z. Guo, X. Zhang, A panel of Transcription factors identified by data mining can predict the prognosis of head and neck squamous cell carcinoma, Cancer Cell Int 19 (2019) 297. 10.1186/s12935-019-1024-6.
25.Q. Liang, C. Xu, X. Chen, X. Li, C. Lu, P. Zhou, L. Yin, R. Qian, S. Chen, Z. Ling, N. Sun, The roles of Mesp family proteins: functional diversity and redundancy in differentiation of pluripotent stem cells and mammalian mesodermal development, Protein Cell 6 (2015) 553-561. 10.1007/s13238-015-0176-y.
26.S. Chabab, F. Lescroart, S. Rulands, N. Mathiah, B.D. Simons, C. Blanpain, Uncovering the Number and Clonal Dynamics of Mesp1 Progenitors during Heart Morphogenesis, Cell Rep 14 (2016). 10.1016/j.celrep.2015.12.013.
27.N. Tandon, K. Goller, F. Wang, B. Soibam, M. Gagea, A.K. Jain, R.J. Schwartz, Y. Liu, Aberrant expression of embryonic mesendoderm factor MESP1 promotes tumorigenesis, EBioMedicine 50 (2019) 55-66. 10.1016/j.ebiom.2019.11.012.
28.S.S.-K. Chan, X. Shi, A. Toyama, R.W. Arpke, A. Dandapat, M. Iacovino, J. Kang, G. Le, H.R. Hagen, D.J. Garry, M. Kyba, Mesp1 patterns mesoderm into cardiac, hematopoietic, or skeletal myogenic progenitors in a context-dependent manner, Cell Stem Cell 12 (2013) 587-601. 10.1016/j.stem.2013.03.004.
29.K. Yamazawa, T. Inoue, Y. Sakemi, T. Nakashima, H. Yamashita, K. Khono, H. Fujita, K. Enomoto, K. Nakabayashi, K. Hata, M. Nakashima, T. Matsunaga, A. Nakamura, K. Matsubara, T. Ogata, M. Kagami, Loss of imprinting of the human-specific imprinted gene causes prenatal growth retardation and dysmorphic features: implications for phenotypic overlap with Silver-Russell syndrome, J Med Genet 58 (2021) 427-432. 10.1136/jmedgenet-2020-107019.
30.R. Xu, S. Li, S. Guo, Q. Zhao, M.J. Abramson, S. Li, Y. Guo, Environmental temperature and human epigenetic modifications: A systematic review, Environ Pollut 259 (2020) 113840. 10.1016/j.envpol.2019.113840.
31.M. Kagami, K. Matsubara, K. Nakabayashi, A. Nakamura, S. Sano, K. Okamura, K. Hata, M. Fukami, T. Ogata, Genome-wide multilocus imprinting disturbance analysis in Temple syndrome and Kagami-Ogata syndrome, Genet Med 19 (2017) 476-482. 10.1038/gim.2016.123.
32.Y. Tanabe, A. Hirano, T. Iwasato, S. Itohara, K. Araki, T. Yamaguchi, T. Ichikawa, T. Kumanishi, Y. Aizawa, H. Takahashi, A. Kakita, H. Nawa, Molecular characterization and gene disruption of a novel zinc-finger protein, HIT-4, expressed in rodent brain, J Neurochem 112 (2010) 1035-1044. 10.1111/j.1471-4159.2009.06525.x.
33.T. Inoue, H. Yagasaki, J. Nishioka, A. Nakamura, K. Matsubara, S. Narumi, K. Nakabayashi, K. Yamazawa, T. Fuke, A. Oka, T. Ogata, M. Fukami, M. Kagami, Molecular and clinical analyses of two patients with UPD(16)mat detected by screening 94 patients with Silver-Russell syndrome phenotype of unknown aetiology, J Med Genet 56 (2019) 413-418. 10.1136/jmedgenet-2018-105463.
34.N. Tarek, D.A. Lee, Natural killer cells for osteosarcoma, Adv Exp Med Biol 804 (2014) 341-353. 10.1007/978-3-319-04843-7_19.
35.L. Fernández, J. Valentín, M. Zalacain, W. Leung, A. Patiño-García, A. Pérez-Martínez, Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner, Cancer Lett 368 (2015) 54-63. 10.1016/j.canlet.2015.07.042.
36.C. Zhang, Y. Hu, C. Shi, Targeting Natural Killer Cells for Tumor Immunotherapy, Front Immunol 11 (2020) 60. 10.3389/fimmu.2020.00060.
37.E.P. Buddingh, M.W. Schilham, S.E.N. Ruslan, D. Berghuis, K. Szuhai, J. Suurmond, A.H.M. Taminiau, H. Gelderblom, R.M. Egeler, M. Serra, P.C.W. Hogendoorn, A.C. Lankester, Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells, Cancer Immunol Immunother 60 (2011) 575-586. 10.1007/s00262-010-0965-3.
38.X. Yang, W. Zhang, P. Xu, NK cell and macrophages confer prognosis and reflect immune status in osteosarcoma, J Cell Biochem (2018). 10.1002/jcb.28167.